Adam Rosenstein
YOU?
Author Swipe
View article: Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease
Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease Open
The human gut includes plasma cells (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elusive regulation, function, and reactivity. We show here that intestinal IgA1+ and IgA2+ PCs co-emerged …
View article: Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis Open
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct coho…
View article: OP39 Vedolizumab response in ulcerative colitis associates with reduced IgG+ plasma cells and FcγR signaling
OP39 Vedolizumab response in ulcerative colitis associates with reduced IgG+ plasma cells and FcγR signaling Open
Background Vedolizumab (VDZ) targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC), its mode of action (MOA) remains unclear. Previously, we documented that response to VDZ is a…
View article: P061 Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes
P061 Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes Open
Background Vedolizumab (VDZ) is a frontline drug for Ulcerative colitis (UC) and Crohn’s disease (CD) that targets integrin α4β7, a gut-homing receptor. Despite significant use, the mechanism(s) of action (MOA) of VDZ remain unclear. Metho…
View article: Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis Open
Targeting the α4β7-MAdCAM-1 axis with vedolizumab (VDZ) is a front-line therapeutic paradigm in ulcerative colitis (UC). However, mechanism(s) of action (MOA) of VDZ remain relatively undefined. Here, we examined three distinct cohorts of …
View article: Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity Open
View article: Identifying the Prevalence of the Impostor Phenomenon Among Computer Science Students
Identifying the Prevalence of the Impostor Phenomenon Among Computer Science Students Open
The Impostor Phenomenon (IP) is often discussed as a problem in the field of computer science, but there has yet to be an empirical study to establish its prevalence among CS students. One survey by the Blind app found that a high number o…
View article: P092 Pathogenic B-cell response in ulcerative colitis that associates with treatment resistance and disease complications
P092 Pathogenic B-cell response in ulcerative colitis that associates with treatment resistance and disease complications Open
Background Among the adaptive immune cells, B cells, dominated by IgA producing plasma cells (PC), are critical for intestinal homeostasis. However, the B-cell response remains under studied in ulcerative colitis (UC). Methods Using single…
View article: Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals Open
Anti-α4β7 integrin therapy results in attrition of lymphoid aggregates within the gastrointestinal tract of HIV-1–infected individuals with IBD.
View article: The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Open
View article: Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals Open
Herein, we present the first human study of anti-α4β7 therapy in a cohort of HIV-1 infected subjects with mild inflammatory bowel disease. α4β7 + gut homing CD4 + T cells are early viral targets and contribute to HIV-1 pathogenesis, likely…
View article: Efficient long‐term depletion of CD20<sup>+</sup> B cells by rituximab does not affect gut‐resident plasma cells
Efficient long‐term depletion of CD20<sup>+</sup> B cells by rituximab does not affect gut‐resident plasma cells Open
The vast majority of antibody‐producing B cells are located within the gastrointestinal tract and are key players in maintaining homeostasis. The failure of rituximab, a potent B cell–depleting agent, to ameliorate ulcerative colitis in a …
View article: Augmentation in Restless Legs Syndrome: Treatment with Gradual Medication Modification
Augmentation in Restless Legs Syndrome: Treatment with Gradual Medication Modification Open
Dopaminergic drugs can cause augmentation during the treatment of restless legs syndrome (RLS). We previously reported that sudden withdrawal of dopaminergic treatment was poorly tolerated. We now report our experience with gradual withdra…